Kiran Ghodke
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kiran Ghodke has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Hari Menon
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India
1 shared publication Kaveri Gadgil
Department of Hematology, Kokilaben Dhirubhai Ambani Hospital and Research Center, Mumbai, Maharashtra, India
1 shared publication- Manju Sengar
Tata Memorial Centre, Mumbai, India
1 shared publication Nikhil Rabade
Department of Hematology, Kokilaben Dhirubhai Ambani Hospital and Research Center, Mumbai, Maharashtra, India
1 shared publicationSameer Tulpule
Department of Hematology and BMT, Kokilaben Dhirubhai Ambani Hospital and Research Center, Mumbai, Maharashtra, India
1 shared publication- Sridhar Epari
Department of Pathology (Including Molecular Pathology Division), Tata Memorial Hospital & ACTREC, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India
1 shared publication
Latest Publications
- Open Access
- 11 May 2026
- Published by Scientific Scholar in Journal of Hematology and Allied Sciences
- Vol. 6, 1-8
Decoding duality: Unraveling biclonal myeloma through flow cytometry and cytogenetics
This report details the case of a 62-year-old female diagnosed with biclonal multiple myeloma (MM), a rare plasma cell proliferative disorder characterized by the simultaneous production of two distinct monoclonal proteins. The patient presented with non-specific symptoms, and initial laboratory and imaging findings were suggestive of typical MM. While serum free light chain assays indicated potential biclonality, traditional serum protein electrophoresis and immunofixation electrophoresis failed to definitively identify two distinct monoclonal light chains. The definitive diagnosis was achieved through multiparametric flow cytometry (MFC), which precisely identified two distinct plasma cell populations with differing light chain restrictions. Further genetic analysis through fluorescent in situ hybridization revealed high-risk cytogenetic abnormalities, including deletion 13q14.2 (RB1/deleted in leukemia (gene locus) [DELU]) and gain of 1q21.22 cyclin-dependent kinase regulatory subunit 1B (CKS1B), alongside hypodiploidy, all correlating with a poor prognosis and potential drug resistance. This case underscores the critical role of advanced diagnostic techniques, particularly MFC, in identifying rare and complex plasma cell dyscrasias and highlights the prognostic significance of co-occurring genetic aberrations in guiding management strategies for this challenging condition.
- 11 May 2026
- Published by Scientific Scholar in Journal of Hematology and Allied Sciences
- Vol. 6, 1-8
Open AccessDecoding duality: Unraveling biclonal myeloma through flow cytometry and cytogenetics
This report details the case of a 62-year-old female diagnosed with biclonal multiple myeloma (MM), a rare plasma cell proliferative disorder characterized by the simultaneous production of two distinct monoclonal proteins. The patient presented with non-specific symptoms, and initial laboratory and imaging findings were suggestive of typical MM. While serum free light chain assays indicated potential biclonality, traditional serum protein electrophoresis and immunofixation electrophoresis failed to definitively identify two distinct monoclonal light chains. The definitive diagnosis was achieved through multiparametric flow cytometry (MFC), which precisely identified two distinct plasma cell populations with differing light chain restrictions. Further genetic analysis through fluorescent in situ hybridization revealed high-risk cytogenetic abnormalities, including deletion 13q14.2 (RB1/deleted in leukemia (gene locus) [DELU]) and gain of 1q21.22 cyclin-dependent kinase regulatory subunit 1B (CKS1B), alongside hypodiploidy, all correlating with a poor prognosis and potential drug resistance. This case underscores the critical role of advanced diagnostic techniques, particularly MFC, in identifying rare and complex plasma cell dyscrasias and highlights the prognostic significance of co-occurring genetic aberrations in guiding management strategies for this challenging condition.
- 1 June 2015
- Published by Elsevier in Annals of Diagnostic Pathology
- Vol. 19 (3) , 117-123
A retrospective study of correlation of morphologic patterns, MIB1 proliferation index, and survival analysis in 134 cases of plasmacytoma
- 1 June 2015
- Published by Elsevier in Annals of Diagnostic Pathology
- Vol. 19 (3) , 117-123
A retrospective study of correlation of morphologic patterns, MIB1 proliferation index, and survival analysis in 134 cases of plasmacytoma